Connection

Co-Authors

This is a "connection" page, showing publications co-authored by NAOTO T UENO and BORJE S ANDERSSON.
Connection Strength

0.285
  1. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93.
    View in: PubMed
    Score: 0.039
  2. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma. 2012 Jun; 53(6):1239-41.
    View in: PubMed
    Score: 0.025
  3. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb; 93(2):257-64.
    View in: PubMed
    Score: 0.019
  4. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005 May; 35(10):943-51.
    View in: PubMed
    Score: 0.016
  5. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2):108-14.
    View in: PubMed
    Score: 0.016
  6. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant. 2004 Sep; 34(6):511-4.
    View in: PubMed
    Score: 0.015
  7. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 01; 104(3):865-72.
    View in: PubMed
    Score: 0.015
  8. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9.
    View in: PubMed
    Score: 0.013
  9. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant. 2002; 8(10):550-6.
    View in: PubMed
    Score: 0.013
  10. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33.
    View in: PubMed
    Score: 0.012
  11. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5.
    View in: PubMed
    Score: 0.012
  12. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001 Apr; 27(8):821-8.
    View in: PubMed
    Score: 0.012
  13. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7.
    View in: PubMed
    Score: 0.012
  14. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20.
    View in: PubMed
    Score: 0.012
  15. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7.
    View in: PubMed
    Score: 0.011
  16. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8.
    View in: PubMed
    Score: 0.011
  17. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70.
    View in: PubMed
    Score: 0.011
  18. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
    View in: PubMed
    Score: 0.011
  19. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug; 16(8):2817-24.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.